1 / 12

Rocky Mountain Cancer Centers Pathways

Rocky Mountain Cancer Centers Pathways. CHOP J4 MAC Conference February 26, 2010. Rocky Mountain Cancer Centers. 65 Physicians 55 medical oncologists 10 radiation oncologists 13 sites of service BMT service in association with PSL Medical Center Part of the US Oncology network.

quade
Télécharger la présentation

Rocky Mountain Cancer Centers Pathways

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rocky Mountain Cancer CentersPathways CHOP J4 MAC Conference February 26, 2010

  2. Rocky Mountain Cancer Centers • 65 Physicians • 55 medical oncologists • 10 radiation oncologists • 13 sites of service • BMT service in association with PSL Medical Center • Part of the US Oncology network

  3. Level I Pathways’ Mission To deliver the highest quality and highest value cancer care to our patients through a physician-driven, network-supported program utilizing evidence-based medicine.

  4. Key Guiding Principles Review the evidence: science comes first! 80/20 Rule: recommend therapies that work for the majority of patients Consider toxicities and safety profile Find the balance point that maximizes patient benefit and accountability for healthcare expenditures Always make clinical trials the first choice for ON-Pathway Generally only provide ON Pathways choices for 1st, 2nd and 3rd line Treating beyond 3rd line without Phase III data demonstrating efficacy is OFF pathways

  5. Level I Pathways Development Process Beginning Review Toxicity Profiles Review & Grade Science Balance Cost To Patient/Payer & Practice Economics Conduct Outcomes Analysis Determine Pathways Using 80/20 Principle Report on Compliance & Exceptions Adopt in Local Practices Provide Point of Care Decision Support Through iKnowMed

  6. Level I Pathway Review Process

  7. What differentiates US Oncology’s Level I Pathways? US Oncology Network Pathways Possible Supported Exceptions FDA Label Or Compendia NCCN Guidelines ASCO Guidelines

  8. Pathways Exception Process Prospective peer review Allow 24-48 hours for response Email utilized for process

  9. Differences in Approach

  10. Current Level I Pathways Solid Tumors Breast Colorectal Ovarian Prostrate Pancreatic NSCLC SCLC Hematological Tumors Hodgkin’s Disease Indolent (Follicular) NHL DLBC Lymphoma Mantle Cell Lymphoma MDS CLL Multiple Myeloma • Hematological Pathway - ITP

More Related